Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

This study tests a combination of two experimental drugs, TQB2930 and TQB2102, both designed to attack cancer cells that have a protein called HER2. The trial enrolls about 178 adults with advanced solid tumors that express HER2 and have not responded to standard treatments. The …

This early-stage trial is testing a new drug called TQB2934 in 42 people with multiple myeloma, a type of blood cancer. TQB2934 is a bispecific antibody designed to help the body's T cells recognize and kill cancer cells. The main goals are to check the drug's safety and how it m…

This study tests a new drug combo (TQB2868 injection plus anlotinib capsules and chemotherapy) as the first treatment for people with advanced pancreatic cancer. About 80 adults aged 18-75 with confirmed pancreatic ductal adenocarcinoma will take part. The goal is to see if the c…

This phase 3 trial tests whether a new drug called TQB2102 works better than the standard treatment (TCbHP) for people with HER2-positive breast cancer before they have surgery. About 544 participants will receive either the new drug or the standard treatment. The main goal is to…

This study tests an experimental drug called TQB2102 in people with advanced bile duct cancer that has a specific marker (HER2-positive). The goal is to see if the drug can shrink tumors or slow the cancer's growth. About 102 adults aged 18 to 75 with good organ function are bein…

This phase 2 trial tests TQB2102, a drug that delivers a powerful toxin directly to cancer cells with a specific genetic change (HER2 abnormality). The study aims to see if the drug can shrink tumors in 270 adults with advanced non-small cell lung cancer that cannot be removed by…

This study tests a new drug called LM-108, which helps the immune system target cancer cells, combined with other cancer drugs (penpulimab and chemotherapy) in people with advanced solid tumors. The goal is to find the right dose and see if the combination is safe and shrinks tum…

This phase 3 trial tests whether a new drug called TQB2930, combined with chemotherapy, works better than the standard drug trastuzumab plus chemotherapy for advanced HER2-positive breast cancer. The study will enroll 416 people who have already received at least two prior anti-H…

This early-phase study tests a new drug called TQB6411 in people with advanced cancers that have not responded to other treatments. The drug works like a guided missile, attaching to specific markers on cancer cells to deliver a toxin that kills them. The main goals are to find a…

This study tests an experimental drug called TQH3906 in adults with moderate-to-severe ulcerative colitis or Crohn's disease. About 135 participants will receive either the drug or a placebo for 12 weeks to see if it safely reduces inflammation and improves symptoms. The goal is …